TipRanks
pc:forxt

FoRx Therapeutics

Basel, Basel 4056, CH
https://www.forxtx.com/
FoRx Therapeutics is a privately held clinical-stage biotechnology company developing precision therapeutics that target the DNA Damage Response (DDR) in treatment-resistant cancers. The company’s lead product candidate, FORX-428, is an oral small-molecule PARG inhibitor in Phase 1 development for advanced solid tumors, aimed at treating cancers resistant to PARP inhibitors.

Leadership & Board

Current Number of Employees34
Current LinkedIn Followers7,332

Latest Estimated Valuation

Estimated Valuation―
Estimated Valuation―
Total Amount Raised$50M
Total Amount Raised$50M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$50M
Latest Funding Amount$50M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―

Employee Trend

FoRx Therapeutics had 34 employees as of September 28, 2026. The number of employees increased by 0 (0.00%) week-over-week.
34Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.

Social Trend

FoRx Therapeutics had 7,332 followers as of September 28, 2026. The number of followers increased by 21 (0.29%) week-over-week.
7,332Latest Followers Count
21(0.29%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Dec 18, 2025
Series A
$50.00M
―

Investors

Investor Name
Funding Round

Similar Companies

A snapshot of private companies similar to FoRx Therapeutics, helping you discover and navigate related company profiles.

Related News and Analysis